Mersana Therapeutics Inc (MRSN) stock is down 5.97% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With MRSN Stock Today?
Mersana Therapeutics Inc (MRSN) stock has fallen -3.38% while the S&P 500 has gained 1.02% as of 12:10 PM on Thursday, May 13. MRSN has fallen -$0.49 from the previous closing price of $14.51 on volume of 279,804 shares. Over the past year the S&P 500 has gained 43.01% while MRSN has gained 37.59%. MRSN lost -$1.58 per share in the over the last 12 months.
To see the top 5 stocks in the Biotechnology industry click here.
More About Mersana Therapeutics Inc
Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.
Click Here to get the full Stock Score Report on Mersana Therapeutics Inc (MRSN) Stock.
